Early empagliflozin initiation after hospitalization for heart failure in the United States: a target trial emulation

9 May 2026 (08:00 - 12:45)

Organised by:

Sign in to view the resources

About the speaker

Professor Stephen Greene

Duke Clinical Research Institute, Durham (United States of America)

5 More presentations in this session

Presentation thumbnail

Timing matters: clinical outcomes of early sodium-glucose cotransporter-2 inhibitor initiation in acute heart failure

Doctor B. Resende (Coimbra, PT)

Presentation thumbnail

Clinical efficacy of sotagliflozin for heart failure outcomes across cardiac biomarker levels in SCORED

Doctor R. Aggarwal (Boston, US)

Presentation thumbnail

Efficacy and safety of finerenone in patients with cardio-kidney-metabolic syndrome and history of cancer: the FINE-HEART pooled analysis

Assistant Professor M. Ruppert (Boston, US)

Presentation thumbnail

Not all creatinine rises are kidney injury, early renal congestion phenotypes in acute heart failure

Mrs E. Vice (Atlanta, US)

Presentation thumbnail

Initiation of mineralocorticoid receptor antagonists in patients with cardiorenal diseases: potassium changes, hyperkalaemia risk and discontinuation in the CaRe study

Unknown S. Greene (Durham, US)

Access the full session

Session thumbnail

Cardiorenal interactions and early therapeutic signals in acute heart failure

The Event

Event poster

Heart Failure 2026

9 May - 12 May 2026

You may be interested in

Congress Session

Guideline-directed medical therapy implementation in special clinical scenarios

Congress Presentation

Audience Q&A

Congress Presentation

Did we forget ARNI in the era of SGLTi?

ESC 365 is supported by

novartis

Explore sponsored resources

ESC 365 is supported by

novartis

Explore sponsored resources